GCLLSG 2016 | Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab
Julia von Tresckow, MD of University of Cologne, Cologne, Germany, discusses the CLL2-BIG trial (NCT02345863), which is one of four trials with the triple-T concept of a tailored and targeted treatment aimed at total eradication of minimal residue disease (MRD). The CLL2-BIG trial is an exploratory Phase II trial designed to show that a combination regimen of ibrutinib and obinutuzumab is safe and efficacious in an all-comer population. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
Get great new content delivered to your inboxSign up